We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.49 | -1.65% | 29.26 | 29.25 | 29.52 | 29.73 | 29.20 | 29.71 | 6,646,430 | 22:20:00 |
From May 2019 to May 2024
By Michael Dabaie
Ionis Pharmaceuticals Inc. (IONS) said Monday its partner Roche (RHHBY) enrolled the first patient in a pivotal study of RG6042 for Huntington's disease.
With the initiation of the study, Ionis said it earned a $35 million milestone payment.
Roche and Ionis are collaborating to develop antisense drugs to treat Huntington's disease. In total, Ionis has generated $135 million in up-front, milestone and license payments and is eligible to receive additional milestone payments as RG6042 progresses in development, as well as royalties.
Huntington's disease is a hereditary neurodegenerative disorder for which there is currently no approved disease-modifying treatment, Ionis said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 28, 2019 07:53 ET (12:53 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
